Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
PharmaTher Holdings Ltd ( (TSE:PHRM) ) just unveiled an announcement.
PharmaTher CEO Fabio Chianelli outlined how 2025 marked a transition from development to validation, highlighted by U.S. FDA approval of the company’s ketamine ANDA and its subsequent sale in a deal structured with upfront payments, milestones and profit-sharing that could exceed US$25 million. With reduced cash burn, a lean operating structure and expected receipts from the ketamine ANDA sale, PharmaTher says it is positioned to pursue 2026 goals without raising additional operating funds, focusing on international ketamine commercialization, strategic partnerships in Parkinson’s disease and drug delivery, monetization of its stake in Sairiyo Therapeutics, and development of next-generation and long-acting ketamine programs and platform tools such as KetaVault and KetAImine to accelerate asset monetization and strengthen its position as an asset-focused value creation company.
The most recent analyst rating on (TSE:PHRM) stock is a Hold with a C$0.10 price target. To see the full list of analyst forecasts on PharmaTher Holdings Ltd stock, see the TSE:PHRM Stock Forecast page.
Spark’s Take on TSE:PHRM Stock
According to Spark, TipRanks’ AI Analyst, TSE:PHRM is a Neutral.
Overall score is held down primarily by weak financial performance (pre-revenue, ongoing losses/negative cash flow, shrinking equity) and bearish technical signals (below major moving averages with negative MACD). Positive corporate events (asset sale and program focus) provide some offset, but valuation support is limited given negative earnings and no dividend yield provided.
To see Spark’s full report on TSE:PHRM stock, click here.
More about PharmaTher Holdings Ltd
PharmaTher Holdings Ltd. is a specialty biopharmaceutical company focused on ketamine-based therapies and asset monetization, including a ketamine franchise and a 49% equity stake in Sairiyo Therapeutics Inc., which is developing a novel oral cepharanthine formulation for infectious diseases and cancer. The company positions itself as an asset-driven platform aiming to generate product revenue, royalty income, equity value and strategic partnerships while emphasizing disciplined cost control and non-dilutive value creation.
Average Trading Volume: 163,561
Technical Sentiment Signal: Sell
Current Market Cap: C$9.56M
See more insights into PHRM stock on TipRanks’ Stock Analysis page.